Antioxidant agents and supplements for nicotinamide mononucleotides

Abstract

The present invention relates to antioxidative agents and supplements against nicotinamide mononucleotides. The present invention addresses the problem of enabling activation of a body by the action of a nicotinamide mononucleotide, that is, enabling activation of cells of the body, and inhibiting active oxygen generated by the action of the nicotinamide mononucleotide by means of hydrogen. The antioxidant action on nicotinamide mononucleotide comprises a first raw material containing nicotinamide mononucleotide and a second raw material containing hydrogen. The second raw material may be a hydrogen-absorbing porous body provided with a ceramic porous body and hydrogen absorbed in the ceramic porous body.

Description

Technical Field

[0001] The present invention relates to an antioxidant agent and a supplement for nicotinamide mononucleotide (hereinafter referred to as "NMN"). Background Art

[0002] As an antioxidant composition for inhibiting aging, for example, Patent Document 1 discloses a composition having an excellent anti-aging effect by containing NMN and at least one selected from the group consisting of pine bark, Lagerstroemia speciosa, and fulvic acid.

[0003] Prior art literature

[0004] Patent Literature

[0005] Patent Document 1: Japanese Patent Application Publication No. 2023-3173 Summary of the invention

[0006] Problem that the invention aims to solve

[0007] NMN is a component that helps activate the body, so the body's cells are activated, but in exchange, the active oxygen that becomes waste increases. Therefore, antioxidants that inhibit this are needed.

[0008] However, the aforementioned composition is said to achieve anti-aging by promoting the expression of SIRTI genes (see paragraph

[0064] ). However, there is no mention of suppressing the generation of active oxygen species due to cell activation in the aforementioned composition.

[0009] The problem of the present invention is to solve the above-mentioned problems under the current situation while considering the description of the above-mentioned Patent Document 1. That is, the problem of the present invention is to activate the body as the effect of NMN, that is, activate the body cells, and further suppress the active oxygen generated by the effect of NMN by hydrogen.

[0010] Solutions for solving problems

[0011] The present invention is as follows.

[0012] 1. The antioxidant agent for NMN of the present invention is characterized by comprising: a first raw material containing NMN, and a second raw material containing hydrogen.

[0013] 2. The antioxidant agent for NMN according to 1. above, wherein the second raw material is a hydrogen storage porous body comprising a ceramic porous body and hydrogen stored in the ceramic porous body.

[0014] 3. The antioxidant agent for NMN according to 1. above, wherein the ceramic porous body is at least one of a silica porous body, a coral porous body and porous carbon.

[0015] 4. The antioxidant agent for NMN according to 2. above, wherein the amount of hydrogen is 0.01 to 99.99% by mass when the hydrogen storage porous body is 100% by mass.

[0016] 5. The antioxidant for NMN according to 1. above, wherein, when the total of NMN contained in the first raw material and hydrogen contained in the second raw material is taken as 100 mass %, the hydrogen is 0.01 to 99.99 mass % and the remainder is NMN.

[0017] 6. A supplement characterized by comprising the antioxidant agent for NMN as described in any one of 1. to 5. above.

[0018] Effects of the Invention

[0019] The present invention can activate the body, that is, activate the body's cells, through the action of NMN, and thereby generate active oxygen, which may have adverse effects on health. Therefore, the active oxygen can be suppressed by the second raw material hydrogen. That is, the present invention can activate the body while suppressing the active oxygen that has adverse effects on health. Therefore, the synergistic effect of the two can appropriately achieve the health of the body and anti-aging. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 It is a graph showing the test results of the 8-OHdG concentration in urine.

[0021] Figure 2 This is a graph showing the test results of the generation rate of 8-OHdG in urine.

[0022] Figure 3 It is a graph showing the test results of 8-OHdG creatinine correction in urine. DETAILED DESCRIPTION

[0023] Hereinafter, the present invention will be described in detail.

[0024] The antioxidant agent for NMN of the present invention is characterized by having a first raw material containing NMN and a second raw material containing hydrogen, and a synergistic combination of the two raw materials. That is, the first raw material of the present invention can activate the body while the second raw material can inhibit the active oxygen generated by the action of NMN. As a result, the two raw materials are the best combination for human health and anti-aging. The present invention is not a simple antioxidant of NMN and hydrogen, but a form of in vivo antioxidant of NMN.

[0025] The aforementioned “antioxidant against NMN” means an antioxidant that is used to inhibit the active oxygen generated by the action of NMN, or in other words, an antioxidant that is used to activate the body and inhibit the active oxygen generated by the action of NMN.

[0026] (1) First raw material

[0027] The first raw material includes NMN.

[0028] The aforementioned NMN is used as a raw material for generating NAD in vivo, and promotes the activation of sirtuin genes. In addition, the aforementioned NMN is a nucleotide derived from ribose and nicotinamide, and is known as an intermediate metabolite involved in the biosynthesis of NAD+ (nicotinamide adenine dinucleotide). The type of optical isomer of this NMN is not limited, for example, the α body or the β body can be used, but the β body is generally used. In addition, the preparation method of the NMN is not particularly limited, and may be a fermentation method using yeast, an enzyme synthesis method, or a chemical synthesis method. In the present invention, humans ingest and use it orally, so for safety reasons, a fermentation method using yeast is preferably used.

[0029] The first raw material may be only NMN, or may have other ingredients, such as nicotinamide riboside (NR) or crystalline cellulose, which are NMN precursors, tablet-forming ingredients, or vitamins or minerals, which contribute to the maintenance and promotion of health, and other cell active ingredients, etc., depending on the purpose and use. In this case, when the first raw material is 100% by mass, the content of NMN can be set to 0.01 to 100% by mass, preferably 1.0 to 100% by mass, and more preferably 10 to 100% by mass.

[0030] The form of the first raw material is not particularly limited and can be formed into various forms according to the purpose and use. For example, its form can be formed into powder, granular, granular, sheet or capsule, etc. The capsule-shaped first raw material can be obtained by filling the components belonging to the first raw material in a capsule container formed by a cylindrical body and a lid. The first raw material is used for oral use by humans, and therefore, the raw material of the capsule container itself is preferably gelatin, a plant-derived raw material (hydroxypropyl methylcellulose, etc.) or pullulan made from cassava starch, etc.

[0031] The particle size of the powder or granules of the first raw material before molding or filling into capsules is about 50 to 500 μm, preferably about 50 to 150 μm.

[0032] Furthermore, in the case of the aforementioned capsule-shaped first raw material, when the other components except the aforementioned capsule container are 100 mass%, the content of the aforementioned NMN can be set to 0.01 to 100 mass%, preferably 1.0 to 100 mass%, and more preferably 10 to 100 mass%.

[0033] The daily intake of NMN for a person can vary depending on the purpose, but can be set to 100-10000 mg / day, 200-5000 mg / day, preferably about 200-1000 mg / day, and more preferably 400-800 mg / day. In addition, considering that the content of NMN per tablet is about 100-300 mg and the daily dosage is about 3 tablets, it can be set to about 300-900 mg. The "person" involved in the aforementioned prescribed intake is considered to be an adult of about 50-60 years old and weighing about 40-70 kg, as tested in the following examples.

[0034] Furthermore, the required amount of the first raw material can be used together with the required intake amount of NMN.

[0035] (2) Second raw material

[0036] The second raw material contains hydrogen.

[0037] As mentioned above, the aforementioned NMN is a component that helps the body activate, but it also increases the reactive oxygen species that become waste instead of activating the body's cells. Therefore, an antioxidant substance that suppresses it is needed, which is hydrogen. It is not simply the antioxidant of NMN and hydrogen, but in the form of in vivo antioxidant of NMN, that is, the hydrogen is used to suppress and reduce the reactive oxygen species in the body generated by the action of NMN in the body.

[0038] The second raw material may contain hydrogen, and other components or constituent substances are not particularly limited. The form of hydrogen is not particularly limited, and may be hydrogen molecules, hydrogen atoms, or hydrogen ions, and is generally considered to be hydrogen molecules.

[0039] Examples of the second raw material containing hydrogen include a hydrogen storage porous body, a clathrate compound storing hydrogen, and liquids such as water in which hydrogen is dissolved. The term "storage" also includes the use of adsorption in a broad sense.

[0040] The hydrogen storage porous body may include a ceramic porous body and hydrogen stored in the ceramic porous body. The ceramic porous body may be at least one of a silica porous body, a coral porous body, and porous carbon.

[0041] The silica porous body has micropores, and hydrogen is stored in the pores, and the size of the pores can be, for example, about 0.1 to 10 nm. Therefore, the hydrogen storage porous body can stably hold hydrogen, and the amount of hydrogen stored is large, so hydrogen can be continuously generated for a long time, and its use duration can also be extended.

[0042] In addition, its surface can be covered with oleic acid, aliphatic higher fatty acids of animal and plant origin, etc. Thus, the porous body enters the body, and the covering film dissolves to generate hydrogen. It can further continue to generate hydrogen for a long time, and its use duration can also be further extended.

[0043] When the hydrogen storage porous body is 100 mass %, the hydrogen content can be 0.01 to 10 mass %, preferably 0.05 to 5.0 mass %, and more preferably 0.1 to 3.0 mass %.

[0044] Furthermore, the required amount of the powder, granules, pellets and flakes (excluding capsule containers) contained in the first raw material can be set according to the required hydrogen uptake amount.

[0045] Furthermore, in the case of the aforementioned capsule-shaped second raw material, when the other components except the aforementioned capsule container are 100 mass%, the content of the aforementioned hydrogen can be set to 0.01 to 100 mass%, preferably 1.0 to 100 mass%, and more preferably 10 to 100 mass%.

[0046] The form of the second raw material is as described in the form of the first raw material, and is not particularly limited, and can be formed into various forms according to the purpose and use. For example, its form can be formed into powder, granules, particles, tablets or capsules.

[0047] The particle size of the second raw material in powder or granular form before molding or filling into capsules is about 50 to 500 μm, preferably about 50 to 150 μm.

[0048] Furthermore, in the case of the aforementioned capsule-shaped second raw material, when the other components except the aforementioned capsule container are 100 mass%, the content of the aforementioned hydrogen raw material can be set to 0.01 to 100 mass%, preferably 1.0 to 100 mass%, and more preferably 10 to 100 mass%.

[0049] Furthermore, the required amount of the powder, granules, pellets and flakes (excluding capsule containers) contained in the second raw material can be set according to the required hydrogen uptake amount.

[0050] (3) Human NMN and hydrogen intake

[0051] The intake of NMN for humans can be set to 100-1500 mg / day, preferably 200-1000 mg / day, and more preferably 400-1000 mg / day. It should be noted that about 3 capsules can be used per day. It can be set to about 100-300 mg per capsule. In the embodiment, it is set to 600 mg / day intake (using 3 capsules of 200 mg / capsule).

[0052] Compared with the above, the intake of hydrogen for humans can be set to 10 to 300 mg / day, preferably 50 to 200 mg / day, and more preferably 80 to 120 mg / day. It should be noted that about 2 capsules can be used per day. It can be set to about 40 to 60 mg per capsule. In the embodiment, it is set to 100 mg / day (using 2 capsules of 50 mg / capsule).

[0053] The intake amount can be set to be an appropriate combination of each intake amount of the aforementioned NMN and each intake amount of the aforementioned hydrogen. In this way, the required amount (intake amount) of the required first raw material and the second raw material can be set.

[0054] (4) Supplements

[0055] This supplement is characterized in that it contains the aforementioned antioxidant for NMN.

[0056] It is generally believed that supplements contribute to the maintenance and promotion of health. The supplement of the present invention not only has hydrogen as the second raw material but also has NMN as the first raw material, and therefore functions as a supplement. In addition, this supplement may also be blended with specific ingredients that contribute to the maintenance and promotion of health, such as vitamins and minerals that are blended in supplements. Furthermore, resveratrol, which is a commonly used supporting ingredient, nicotinamide riboside (NR), which is a precursor of NMN, vitamin B1, vitamin B2, vitamin B6, and nicotinamide may also be blended.

[0057] Additionally, regarding the capsules used in this supplement, the previous instructions apply directly.

[0058] That is, the shape or form of the supplement may be, as usual, a granular or tablet obtained by compressing or molding a raw material such as a specified powder, or a capsule-shaped body filled with a specified raw material in a cylindrical body and a lid. The capsule is used for oral use, and therefore, preferably uses gelatin, a plant-derived raw material (hydroxypropyl methylcellulose, etc.), or pullulan made from cassava starch, etc.

[0059] Furthermore, the first raw material and the second raw material may be formed into tablets or capsules, respectively. In addition, a separator may be provided in one capsule to contain each powder or tablet, etc., so that the two raw materials do not directly contact each other, or the other may be formed into a small capsule and contained in a large capsule.

[0060] The intake amount of the aforementioned supplement may also be the same as that shown in the aforementioned "NMN and hydrogen intake amount for humans" column.

[0061] Example

[0062] Hereinafter, the present invention will be described in further detail based on examples, but the present invention is not limited to these examples, and the present invention can adopt various modes as long as the subject of the present invention can be solved.

[0063] (1) Test methods;

[0064] As an experiment, the NMN intake group and the NMN + hydrogen intake group used the antioxidant marker 8-OHdG (8-hydroxydeoxyguanosine) in urine to test how the antioxidant status of 8-OHdG in the body changes. That is, if the human body is prone to oxidation, part of the nucleic acid is oxidized, and 8-OHdG gradually appears in the urine. The 8-OHdG is measured.

[0065] The specific method is as follows: The types and compositions of the raw materials used are as follows.

[0066] The first raw material used is a first supplement containing NMN, and the second raw material is a second supplement formed of a hydrogen absorbing ceramic porous body (a raw material in which hydrogen is absorbed in a porous body formed of silicon dioxide). The compounding components and their compounding ratios of the first raw material are as follows.

[0067] NMN (30-75 mass%)

[0068] Crystalline cellulose (20-40% by mass)

[0069] Micro-silicon dioxide (1-2 mass%)

[0070] Calcium stearate (0.5-2 mass%)

[0071] Oleic acid (1-5 mass%)

[0072] Hydrogen raw material (0.5-25 mass%)

[0073] In addition, three test subjects (A, B, and C), sample collection dates (September 4, September 7, and September 14), urine storage volume, urine storage time, etc. are shown in Table 1. "F" indicates female.

[0074] [Table 1]

[0075] Tests of urine storage volume and duration

[0076]

[0077] Preparation for further experiments was as follows.

[0078] Each subject was allowed to carry out normal daily life and dietary intake, and was not allowed to take any supplements.

[0079] (a) Day 0; morning urine collection was performed.

[0080] After that, the first supplement of NMN was started, and the NMN intake at this time was 600 mg / day (200 mg / tablet × 3 tablets / day).

[0081] (b) Day 3: Collect urine in the morning.

[0082] After that, start taking the first (NMN) and second supplement (hydrogen) mentioned above.

[0083] The hydrogen source at this time was taken at 100 mg / day (50 mg / pill×2 pills / day).

[0084] (c) Day 10: Collect urine in the morning.

[0085] The first and second supplements were taken in separate capsules. No specific intake time target was set for each day of intake.

[0086] This time, 3 capsules of the first capsule were taken per day, and 2 capsules of the second capsule were taken per day.

[0087] (2) Test results:

[0088] Urinary 8-OHdG was analyzed, and the results are shown in Table 2. "F" indicates female.

[0089] [Table 2]

[0090] Urinary 8-OHdG test

[0091]

[0092] The urine sample collected in the morning was frozen in dry ice and sent to an analysis institution together with the dry ice for analysis.

[0093] The analysis results are shown in Table 1 and Figures 1 to 3 They showed three results: no use of NMN and hydrogen, use of NMN alone, and use of both. Figures 1 to 3 The comparison results of the above three conditions for each subject are shown. Figure 1 Shows 8-OHdG in urine, Figure 2 Shows the rate of 8-OHdG production in urine, Figure 3 The results corrected for 8-OHdG creatinine in urine are shown.

[0094] In addition, the creatinine correction value was calculated by the following formula.

[0095] Creatinine correction value (mg / g·Cre) = measured value (mg / dl) × 1000 / Cre concentration (mg / dl)

[0096] The significance of this creatinine correction is as follows.

[0097] That is, creatinine is the final metabolite of creatine, and is used for urine volume error due to its constant excretion. The excretion of urine components and urine volume fluctuate daily, and there is a possibility of false positives and false negatives based on urine collection at any time. Therefore, if creatinine correction is used, even if 24-hour urine storage is not performed, evaluation can be performed based on urine collection at this time.

[0098] Compared with the case without NMN (Comparative Example), Figure 3 Except for the case of creatinine correction of A, all other urinary 8-OHdG concentrations, urinary 8-OHdG generation rates, and urinary 8-OHdG creatinine correction decreased, indicating the effect of NMN. However, even if there is an effect of NMN use, as shown in the results of the case of combined use of hydrogen, it is judged that it has not decreased to this extent.

[0099] In addition, the case of taking both (the present invention example) was compared with the case of taking only NMN (the comparative example). Figure 3 Except for the case of creatinine correction of C, all other urinary 8-OHdG concentrations, urinary 8-OHdG production rate and urinary 8-OHdG creatinine correction were reduced. Compared with the case of using NMN alone, the case of using both NMN and hydrogen in the present invention showed excellent effects.

[0100] In addition, the concentration of 8-OHdG in urine was significantly higher in the case of taking both (the present invention example) than in the case of not taking both (the comparative example). Figure 1 ), 8-OHdG generation rate in urine ( Figure 2 ) and 8-OHdG creatinine correction in urine ( Figure 3 ) were significantly reduced, with the ratios being 1 / 29, 1 / 1.8, and 1 / 3.0 ( Figure 1 )、1 / 13、1 / 4.8、1 / 2.4( Figure 2 )、1 / 2.5、1 / 2.2、1 / 1.3( Figure 3 ), the examples of the present invention all showed very excellent effects.

[0101] Furthermore, the concentration of 8-OHdG in urine was significantly lower in the case of taking both (the present invention example) than in the case of taking only NMN (the comparative example). Figure 1), 8-OHdG generation rate in urine ( Figure 2 ) and 8-OHdG creatinine correction in urine ( Figure 3 ), only the case of C remained basically unchanged, but the other cases were greatly reduced, and the ratios of these values ​​were 1 / 19, 1 / 1.4, and 1 / 1.1 ( Figure 1 )、1 / 6.9、1 / 3.2、1 / 1.0( Figure 2 )、1 / 2.9、1 / 1.7、1 / 1.0( Figure 3 ), the examples of the present invention all showed very excellent effects.

[0102] In view of the above aspects, the embodiments of the present invention show a large synergistic effect based on the combination of two raw materials.

[0103] Industrial Applicability

[0104] The present invention has the effect of improving human health and preventing aging, and is widely used in health foods, supplements, and medicines, and is used to promote industries related to these.

Claims

1. An antioxidant agent for nicotinamide mononucleotide, characterized in that: The method comprises: a first raw material including nicotinamide mononucleotide, and a second raw material including hydrogen.

2. The antioxidant agent for nicotinamide mononucleotide according to claim 1, wherein The second raw material is a hydrogen storage porous body including a ceramic porous body and hydrogen stored in the ceramic porous body.

3. The antioxidant agent for nicotinamide mononucleotide according to claim 2, wherein The ceramic porous body is at least one of a silica porous body, a coral porous body, and porous carbon.

4. The antioxidant agent for nicotinamide mononucleotide according to claim 2, wherein When the hydrogen storage porous body is taken as 100 mass %, the hydrogen is in the range of 0.01 to 99.99 mass %.

5. The antioxidant agent for nicotinamide mononucleotide according to claim 1, wherein When the total amount of the nicotinamide mononucleotide contained in the first raw material and the hydrogen contained in the second raw material is 100 mass %, the hydrogen is 0.01 to 99.99 mass % and the remainder is the nicotinamide mononucleotide.

6. A supplement, characterized in that An agent having an antioxidant effect on nicotinamide mononucleotide comprising any one of claims 1 to 5.

Images